Bullish
Henry Schein reported modest Q1 2026 revenue growth and raised its full-year outlook, driven by resilient demand in dental and medical markets. The co...
Neutral
Henry Schein, Inc. shares fell 5.5% despite reporting an 8.1% EPS beat, with statutory profit of US$0.92 per share exceeding expectations. Analysts ha...
Henry Schein (NASDAQ: HSIC) reported strong financial results for Q1 2026, with net sales increasing by 6.3% to $3.37 billion and non-GAAP diluted EPS...
Bullish
Henry Schein, Inc. reported strong first-quarter 2026 financial results, with total net sales increasing by 6.3% to $3.4 billion and non-GAAP diluted ...
Bullish
Henry Schein, Inc. announced its participation in two investor conferences in May: the Bank of America Healthcare Conference on May 13th and the Stife...
Neutral
Henry Schein, Inc. (Nasdaq: HSIC) announced its participation in two investor conferences in May: the Bank of America Healthcare Conference on May 13 ...
Neutral
Henry Schein (NASDAQ:HSIC) was downgraded by Wall Street Zen from a "strong-buy" to a "buy" rating, with the overall analyst consensus remaining "Hold...
Neutral
Henry Schein, Inc. (HSIC) is undergoing a significant board restructuring, reducing its size from fifteen to ten members following long-time director ...